BioNTech SE (VIE:BNTX)
Austria · Delayed Price · Currency is EUR 80.35
+2.20 (2.82%)
At close: Aug 7, 2026
BioNTech SE Financials Overview
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,426 | 3,055 | 2,892 | 3,924 | 17,311 | 18,977 |
Revenue Growth | -0.35% | 5.63% | -26.31% | -77.33% | -8.78% | 3834.63% |
Gross Profit Gross Profit Growth | 1,776 | 2,413 | 2,350 | 3,324 | 14,316 | 16,065 |
Operating Income Operating Income Growth | -1,995 | -1,405 | -1,314 | 690.4 | 12,643 | 15,284 |
Net Income Net Income Growth | -1,686 | -1,136 | -665.3 | 930.3 | 9,434 | 10,293 |
Earnings Per Share EPS Growth | -6.71 | -4.70 | -2.77 | 3.83 | 37.77 | 39.63 |
EPS Growth | - | - | - | -89.86% | -4.69% | 65950.00% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
COVID-19 Vaccine COVID-19 Vaccine Growth | 1,828 | 1,995 | 2,432 | 3,776 | 17,145 |
Out-Licensing Out-Licensing Growth | - | 613 | - | - | - |
Other Sales Other Sales Growth | 209.2 | 261.6 | 319 | 42.8 | 165.4 |
Revenue (Total) Revenue (Total) Growth | 2,426 | 3,055 | 2,892 | 3,924 | 17,311 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 14,779 | 14,877 | 16,784 | 16,549 | 14,065 | 2,074 |
Total Debt Total Debt Growth | 316.1 | 267.4 | 254.2 | 219.1 | 212.2 | 301.5 |
Net Cash (Debt) Net Cash Growth | 14,463 | 14,610 | 16,529 | 16,330 | 13,852 | 1,773 |
Net Cash Growth | 5.05% | -11.61% | 1.22% | 17.89% | 681.38% | 60.10% |
Net Cash Per Share Net Cash Per Share Growth | 57.55 | 60.45 | 68.76 | 67.28 | 55.45 | 6.83 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 679.7 | 456 | 207.7 | 5,371 | 13,577 | 889.7 |
Capital Expenditures CapEx Growth | -210.5 | -175.1 | -286.5 | -249.4 | -329.2 | -127.5 |
Free Cash Flow Free Cash Flow Growth | 469.2 | 280.9 | -78.8 | 5,122 | 13,248 | 762.2 |
Free Cash Flow Growth | - | - | - | -61.34% | 1638.15% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 73.21% | 78.99% | 81.28% | 84.71% | 82.70% | 84.66% |
Operating Margin | -82.24% | -45.99% | -45.45% | 17.59% | 73.03% | 80.54% |
Pretax Margin | -67.16% | -34.40% | -23.44% | 30.23% | 74.83% | 79.29% |
Profit Margin | -69.50% | -37.19% | -23.01% | 23.71% | 54.50% | 54.24% |
FCF Margin | 19.34% | 9.20% | -2.73% | 130.53% | 76.53% | 4.02% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 24.93 | 3.71 | 5.72 |
Forward PE | - | 100.62 | 100.62 | 67.81 | 8.27 | 8.07 |
P/FCF Ratio | 43.38 | 72.60 | - | 4.43 | 2.57 | 72.14 |
PS Ratio | 7.68 | 6.68 | 9.09 | 5.78 | 1.97 | 2.90 |